Feng Xu, Chai Yi-Han, Jiang Ke-Xin, Jiang Wen-Bin, Chen Wen-Chao, Pan Yu
Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China.
World J Gastrointest Oncol. 2024 Nov 15;16(11):4489-4505. doi: 10.4251/wjgo.v16.i11.4489.
Genetic screening for breast cancer gene 1 ()/ mutations can inform breast/ovarian/pancreatic cancer patients of suitable therapeutic interventions. Four to seven percent of pancreatic cancer patients have germline mutations. genes aid in DNA repair, especially homologous recombination, which impacts genomic stability and cancer cell growth. regulates the cell cycle, ubiquitination, and chromatin remodeling, whereas stimulates the immune response. They predict the efficacy of platinum chemotherapy or polymerase (PARP) inhibitors such as olaparib.
To determine the trends and future directions in the use of olaparib for pancreatic cancer treatment.
To evaluate the trends in how olaparib works in pancreatic cancer, we performed a bibliometric analysis. One hundred and ninety-six related publications were accessed from the Web of Science Core Collection and were published between 2009 and 2022. The analytic parameters included publications, related citations, productive countries and institutes, influential authors, and keyword development.
This study visualizes and discusses the current research, including the present global trends and future directions in olaparib and pancreatic cancer. Overall, this study sheds light on optimizing the use of olaparib in pancreatic cancer treatment, offering valuable guidance for researchers in this field.
Our findings identified trends in olaparib and pancreatic cancer, with China and the USA leading and with global cooperation tightening. O'Reilly EM's team and Memorial Sloan-Kettering had the highest output. The was the most cited journal. More PARP inhibitors are emerging, and combination therapy is suggested for future therapeutic trends.
乳腺癌基因1（）/突变的基因筛查可为乳腺癌/卵巢癌/胰腺癌患者提供合适的治疗干预信息。4%至7%的胰腺癌患者存在种系突变。基因有助于DNA修复，尤其是同源重组，这会影响基因组稳定性和癌细胞生长。调节细胞周期、泛素化和染色质重塑，而刺激免疫反应。它们可预测铂类化疗或聚腺苷酸聚合酶（PARP）抑制剂（如奥拉帕利）的疗效。
确定奥拉帕利用于胰腺癌治疗的趋势和未来方向。
为评估奥拉帕利在胰腺癌中的作用趋势，我们进行了文献计量分析。从科学引文索引核心合集检索到196篇相关出版物，发表时间为2009年至2022年。分析参数包括出版物、相关引文、高产国家和机构、有影响力的作者以及关键词发展情况。
本研究可视化并讨论了当前的研究，包括奥拉帕利和胰腺癌的当前全球趋势及未来方向。总体而言，本研究阐明了优化奥拉帕利在胰腺癌治疗中的应用，为该领域的研究人员提供了有价值的指导。
我们的研究结果确定了奥拉帕利和胰腺癌的趋势，中国和美国处于领先地位，全球合作日益紧密。奥赖利·E·M的团队和纪念斯隆凯特琳癌症中心的产出最高。《》是被引用最多的期刊。越来越多的PARP抑制剂正在出现，建议联合治疗作为未来的治疗趋势。
